ドーパミン作動薬の世界市場レポート 2025年

ドーパミン作動薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.5％で36億9,000万米ドルに成長します。予測期間中の成長は、神経疾患の有病率の上昇、世界人口の高齢化、研究と臨床試験の増加、併用療法の拡大、認知度と診断率の上昇に起因すると考えられます。この期間に予想される主な動向には、個別化医療と遺伝子プロファイリングの利用、ウェアラブルドラッグデリバリーシステムの開発、医薬品開発におけるAIと機械学習の統合、徐放性製剤の進歩、ドラッグデリバリーへのナノテクノロジーの応用などがあります。

神経疾患の罹患率の上昇は、ドパミンアゴニスト市場の成長を著しく促進すると予想されます。脳、脊椎、神経に影響を及ぼす神経疾患は、運動、認知、行動に関連する問題を引き起こします。このような有病率の増加は、アルツハイマー病やパーキンソン病などの疾患が加齢とともに一般的になるため、平均寿命が長くなったことが主な原因です。ドーパミン作動薬は、脳内のドーパミン受容体を刺激することにより、パーキンソン病などの疾患の治療に使用され、運動制御を強化し、症状を緩和するのに役立ちます。例えば、アルツハイマー病のケア、サポート、研究に焦点を当てた米国の非営利団体であるアルツハイマー病協会（Alzheimer's Association）が発表した「Alzheimer's Disease Facts and Figures」レポートによると、2022年には65歳以上のアメリカ人のうち650万人がアルツハイマー型認知症と診断され、その数は2024年までに690万人に増加すると予測されています。その結果、神経疾患の有病率の増加は、ドパミン作動薬市場の拡大を牽引し続けると思われます。

ドパミン作動薬市場の主要企業は、患者の服薬アドヒアランスを高め、副作用を最小限に抑え、神経疾患に対してよりオーダーメイドの治療ソリューションを提供するため、フレキシブル用量単剤療法などのイノベーションに注力しています。フレキシブルドーズ単剤療法は、投与量を調整可能な単剤療法であり、ヘルスケアプロバイダーは患者固有のニーズや反応に基づいて治療をカスタマイズすることができます。例えば、2024年11月、米国のバイオ医薬品会社であるアッヴィ社は、第3相TEMPO-2試験で良好な結果が得られたと報告しました。同試験は、MDS-UPDRSパートIIおよびIIIスコアの大幅な低下という主要目標を達成し、日常運動動作の有意な改善という重要な副次的目標を達成しました。タバパドンは、1日1回投与のパーキンソン病治療薬として検討されている初めてのD1/D5パーシャルアゴニストです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ドーパミン作動薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のドーパミン作動薬市場：成長率分析
• 世界のドーパミン作動薬市場の実績：規模と成長, 2019-2024
• 世界のドーパミン作動薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ドーパミン作動薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のドーパミン作動薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 麦角ベースのドーパミン作動薬
• 麦角質を含まないドーパミン作動薬
• 世界のドーパミン作動薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 経皮パッチ
• 世界のドーパミン作動薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の薬局
• 世界のドーパミン作動薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• パーキンソン病
• むずむず脚症候群（RLS）
• 高プロラクチン血症
• 世界のドーパミン作動薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ケア設定
• 世界のドーパミン作動薬市場麦角系ドーパミン作動薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブロモクリプチン
• カベルゴリン
• ペルゴリド
• 世界のドーパミン作動薬市場非麦角系ドーパミン作動薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラミペキソール
• ロピニロール
• ロチゴチン
• アポモルフィン

第7章 地域別・国別分析

• 世界のドーパミン作動薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のドーパミン作動薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ドーパミン作動薬市場：競合情勢
• ドーパミン作動薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Otsuka Pharmaceutical Co. Ltd.
• Intas Pharmaceuticals Ltd.
• UCB Pharma S.A.
• Dr. Reddy's Laboratories Ltd.
• H. Lundbeck A/S
• Lupin Limited
• Luye Pharma Group Ltd.
• ACADIA Pharmaceuticals Inc.
• Kissei Pharmaceutical Co., Ltd.
• Shodhana Laboratories Pvt. Ltd.
• Oceanic Pharmachem Pvt. Ltd.
• AffaMed Therapeutics Holdings Limited
• Schwarz Pharma AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ドーパミン作動薬市場2029：新たな機会を提供する国
• ドーパミン作動薬市場2029：新たな機会を提供するセグメント
• ドーパミン作動薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Dopamine agonists are medications that activate dopamine receptors in the brain, mimicking the effects of natural dopamine. These medications are commonly used to manage disorders caused by low dopamine activity or impaired dopamine signaling.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of dopamine agonists are ergot-based dopamine agonists and non-ergot-based dopamine agonists. Ergot-based dopamine agonists are derived from ergot alkaloids and work by activating dopamine receptors in the brain to help manage neurological and hormonal conditions. These medications are available in various forms, including oral, parenteral (injectable), and transdermal patches. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, and other pharmacy outlets. Ergot-based dopamine agonists are commonly used in the treatment of conditions such as Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia. Key end users include hospitals, clinics, and home care settings.

The dopamine agonist market research report is one of a series of new reports from The Business Research Company that provides dopamine agonist market statistics, including the dopamine agonist industry global market size, regional shares, competitors with the dopamine agonist market share, detailed dopamine agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the dopamine agonist industry. This dopamine agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dopamine agonists market size has grown strongly in recent years. It will grow from$2.57 billion in 2024 to $2.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to the increasing incidence of Parkinson's disease, a rise in the diagnosis of restless legs syndrome (RLS), expansion of reimbursement coverage, growing research funding for central nervous system (CNS) disorders, and increasing healthcare awareness.

The dopamine agonists market size is expected to see strong growth in the next few years. It will grow to$3.69 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth during the forecast period can be attributed to the rising prevalence of neurological disorders, the aging global population, an increase in research and clinical trials, the expansion of combination therapies, and rising awareness and diagnosis rates. Key trends expected during this period include the use of personalized medicine and genetic profiling, the development of wearable drug delivery systems, the integration of AI and machine learning in drug development, advancements in extended-release formulations, and the application of nanotechnology for drug delivery.

The rising incidence of neurological disorders is expected to significantly drive the growth of the dopamine agonist market. Neurological disorders, which impact the brain, spine, or nerves, cause issues related to movement, cognition, and behavior. This increase in prevalence is largely due to longer life expectancies, as conditions such as Alzheimer's and Parkinson's become more common with age. Dopamine agonists are used to treat disorders such as Parkinson's disease by stimulating dopamine receptors in the brain, helping to enhance motor control and alleviate symptoms. For example, the Alzheimer's Disease Facts and Figures report from the Alzheimer's Association, a US-based nonprofit focused on Alzheimer's care, support, and research, indicates that in 2022, 6.5 million Americans aged 65 and older were diagnosed with Alzheimer's dementia, a number projected to rise to 6.9 million by 2024. As a result, the growing prevalence of neurological disorders will continue to drive the expansion of the dopamine agonist market.

Leading companies in the dopamine agonist market are focusing on innovations such as flexible-dose monotherapy to enhance patient adherence, minimize side effects, and offer more tailored treatment solutions for neurological disorders. Flexible-dose monotherapy involves a single drug with an adjustable dosage, allowing healthcare providers to customize the treatment based on the patient's unique needs and responses. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, reported positive results from its Phase 3 TEMPO-2 trial, where investigational tavapadon, a flexible-dose monotherapy (5-15 mg once daily), showed significant improvements in motor function among early Parkinson's disease patients. The trial met its primary goal with a substantial reduction in MDS-UPDRS Parts II and III scores and achieved important secondary objectives, indicating meaningful improvements in daily motor activities. Tavapadon is the first D1/D5 partial agonist being investigated for once-daily Parkinson's treatment.

In August 2024, AbbVie, a US-based biopharmaceutical company, acquired Cerevel Therapeutics for $8.7 billion. This strategic acquisition allows AbbVie to enhance its neuroscience portfolio by gaining access to Cerevel's innovative pipeline of treatments targeting psychiatric and neurological disorders. Cerevel Therapeutics Holdings Inc. is a US-based biopharmaceutical company focused on developing therapies for neurological and psychiatric conditions.

Major players in the dopamine agonists market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., UCB Pharma S.A., Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd., ACADIA Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd., Shodhana Laboratories Pvt. Ltd., Oceanic Pharmachem Pvt. Ltd., AffaMed Therapeutics Holdings Limited, Schwarz Pharma AG

North America was the largest region in the dopamine agonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dopamine agonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dopamine agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dopamine agonist market includes sales of pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine, and cabergoline. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dopamine Agonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dopamine agonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dopamine agonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dopamine agonists market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Ergot Based Dopamine Agonists; Non Ergot Based Dopamine Agonists
• 2) By Route of Administration: Oral; Parenteral; Transdermal Patches
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
• 4) By Application: Parkinson's Disease; Restless Legs Syndrome (RLS); Hyperprolactinemia
• 5) By End User: Hospitals; Clinics; Home Care Settings
• Subsegments::
• 1) Ergot-Based Dopamine Agonists: Bromocriptine; Cabergoline; Pergolide
• 2) Non-Ergot-Based Dopamine Agonists: Pramipexole; Ropinirole; Rotigotine; Apomorphine
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dopamine Agonists Market Characteristics

3. Dopamine Agonists Market Trends And Strategies

4. Dopamine Agonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Dopamine Agonists Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dopamine Agonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dopamine Agonists Market Growth Rate Analysis
• 5.4. Global Dopamine Agonists Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dopamine Agonists Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dopamine Agonists Total Addressable Market (TAM)

6. Dopamine Agonists Market Segmentation

• 6.1. Global Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ergot Based Dopamine Agonists
• Non Ergot Based Dopamine Agonists
• 6.2. Global Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Transdermal Patches
• 6.3. Global Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies
• 6.4. Global Dopamine Agonists Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parkinson's Disease
• Restless Legs Syndrome (RLS)
• Hyperprolactinemia
• 6.5. Global Dopamine Agonists Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings
• 6.6. Global Dopamine Agonists Market, Sub-Segmentation Of Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bromocriptine
• Cabergoline
• Pergolide
• 6.7. Global Dopamine Agonists Market, Sub-Segmentation Of Non Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pramipexole
• Ropinirole
• Rotigotine
• Apomorphine

7. Dopamine Agonists Market Regional And Country Analysis

• 7.1. Global Dopamine Agonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dopamine Agonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dopamine Agonists Market

• 8.1. Asia-Pacific Dopamine Agonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dopamine Agonists Market

• 9.1. China Dopamine Agonists Market Overview
• 9.2. China Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dopamine Agonists Market

• 10.1. India Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dopamine Agonists Market

• 11.1. Japan Dopamine Agonists Market Overview
• 11.2. Japan Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dopamine Agonists Market

• 12.1. Australia Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dopamine Agonists Market

• 13.1. Indonesia Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dopamine Agonists Market

• 14.1. South Korea Dopamine Agonists Market Overview
• 14.2. South Korea Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dopamine Agonists Market

• 15.1. Western Europe Dopamine Agonists Market Overview
• 15.2. Western Europe Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dopamine Agonists Market

• 16.1. UK Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dopamine Agonists Market

• 17.1. Germany Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dopamine Agonists Market

• 18.1. France Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dopamine Agonists Market

• 19.1. Italy Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dopamine Agonists Market

• 20.1. Spain Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dopamine Agonists Market

• 21.1. Eastern Europe Dopamine Agonists Market Overview
• 21.2. Eastern Europe Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dopamine Agonists Market

• 22.1. Russia Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dopamine Agonists Market

• 23.1. North America Dopamine Agonists Market Overview
• 23.2. North America Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dopamine Agonists Market

• 24.1. USA Dopamine Agonists Market Overview
• 24.2. USA Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dopamine Agonists Market

• 25.1. Canada Dopamine Agonists Market Overview
• 25.2. Canada Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dopamine Agonists Market

• 26.1. South America Dopamine Agonists Market Overview
• 26.2. South America Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dopamine Agonists Market

• 27.1. Brazil Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dopamine Agonists Market

• 28.1. Middle East Dopamine Agonists Market Overview
• 28.2. Middle East Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dopamine Agonists Market

• 29.1. Africa Dopamine Agonists Market Overview
• 29.2. Africa Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dopamine Agonists Market Competitive Landscape And Company Profiles

• 30.1. Dopamine Agonists Market Competitive Landscape
• 30.2. Dopamine Agonists Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Dopamine Agonists Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Otsuka Pharmaceutical Co. Ltd.
• 31.4. Intas Pharmaceuticals Ltd.
• 31.5. UCB Pharma S.A.
• 31.6. Dr. Reddy's Laboratories Ltd.
• 31.7. H. Lundbeck A/S
• 31.8. Lupin Limited
• 31.9. Luye Pharma Group Ltd.
• 31.10. ACADIA Pharmaceuticals Inc.
• 31.11. Kissei Pharmaceutical Co., Ltd.
• 31.12. Shodhana Laboratories Pvt. Ltd.
• 31.13. Oceanic Pharmachem Pvt. Ltd.
• 31.14. AffaMed Therapeutics Holdings Limited
• 31.15. Schwarz Pharma AG

32. Global Dopamine Agonists Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dopamine Agonists Market

34. Recent Developments In The Dopamine Agonists Market

35. Dopamine Agonists Market High Potential Countries, Segments and Strategies

• 35.1 Dopamine Agonists Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dopamine Agonists Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dopamine Agonists Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34827_Dopamine_Agonists_GMR_2025